A Doctor Says Mast Cells Cause Lipedema. Show Us the Evidence.

If you tell women what causes their lipedema—and what must be treated before they can improve—you need research that supports those claims.

I live with lipedema. I want better answers. I want research that leads to better treatment. And when someone says they have an explanation for what is happening in our bodies, I pay attention.

But I also want to know whether that explanation has actually been demonstrated.

In an Instagram caption, Dr. Tania Dempsey writes:

“Mast cells drive the inflammation that causes fat accumulation, fibrosis, and scarring in lipedema.”

The caption also says these changes will not adequately resolve until underlying mast cell activation syndrome, or MCAS, is addressed. It invites viewers to a podcast discussing whether lipedema can “actually reverse.” Her caption was captured and quoted as of October 29, 2026.

That is a lot for the evidence to carry.

The research reviewed here does not establish MCAS as the cause of lipedema or demonstrate that mast-cell treatment reverses it. There are findings worth investigating. There are also substantial gaps between those findings and the claims being made.

This article evaluates that specific public caption against published research. It does not question Dr. Dempsey’s qualifications, character, or motives, and it does not assess any care she provides patients.

Let’s look at those gaps in ordinary language.

What did the researchers actually find?

A 2023 study compared fat samples from 44 women with lipedema and 18 controls. The researchers found higher levels of histamine in the lipedema samples.

That matters. It gives researchers something to investigate. But finding more of a chemical in affected tissue does not establish whether it helped cause the disease, appeared because of the disease, or is part of a more complicated process.

The same paper also described treatment with a mast-cell-stabilizing drug, sodium cromoglycate, in three participants for about two weeks. The researchers reported lower histamine levels in their tissue after treatment.

Three people. About two weeks.

The study did not establish improvements in pain, movement, fat accumulation, or fibrosis. It did not demonstrate that lipedema reversed.

A change in a tissue measurement does not automatically mean someone’s life or condition improved.

That is the missing step when an early research finding becomes a confident treatment message.

Another study, published in 2019, compared 30 people with lipedema and 19 controls. It found no significant difference in mast-cell numbers between the groups. That does not rule out differences in how those cells behave. It does mean the evidence cannot be reduced to a simple story about people with lipedema having more mast cells.

There are questions here that deserve research. The answers are still developing.

Mast-cell involvement does not automatically mean MCAS

This is another distinction that gets lost in a fast-moving video.

Mast cells are immune cells. Researchers can investigate what they are doing in a particular tissue without establishing that the people studied have mast cell activation syndrome.

MCAS is a specific diagnosis with its own assessment criteria. Those include an appropriate pattern of symptoms, evidence of mast-cell chemical release during episodes, and a response to treatment. Finding histamine in a tissue sample does not, by itself, establish that diagnosis.

So there are several separate questions:

• Are mast cells involved in some aspects of lipedema?
• Does a particular person also have MCAS?
• Does treating that person’s MCAS improve their symptoms?
• Does that treatment change or reverse lipedema itself?

Evidence answering one question cannot simply be used as the answer to all four.

A person’s MCAS deserves appropriate assessment and care. That still does not establish MCAS as the explanation for everyone’s lipedema.

And we need to be more precise about diet and exercise

The reel also says lipedema has “nothing to do with your diet” and “nothing to do with how much you exercise.”

That wording needs care.

If the message is that women should not be blamed for their lipedema, I agree. Having this condition is not a character flaw.

But what causes a condition and what helps someone manage it are different questions. If viewers come away believing nutrition and movement cannot help, they are missing evidence that matters.

In an eight-week randomized trial involving 70 women with lipedema and obesity, researchers compared two calorie-restricted diets. The lower-carbohydrate group had a greater reduction in current pain. Both groups improved in several areas of quality of life.

That was a short study in a specific group of women. It does not establish a cure or tell every person with lipedema which diet to follow. But it provides direct evidence that dietary treatment can affect symptoms—not just a vague suggestion that eating well is generally good for you.

Movement research is still developing, too. A six-week trial involving 33 women with severe lipedema reported improvements across exercise-based treatment programs. Adding complete decongestive therapy produced greater improvements in some outcomes, including pain and physical functioning. Because everyone exercised, the study could not isolate the effect of exercise itself.

The 2026 Lipedema World Alliance consensus also includes nutrition and adapted movement in care, while acknowledging that the evidence varies and treatment needs to fit the individual.

A treatment does not have to cure lipedema to offer something worthwhile.

Less pain matters. Better function matters. Being able to do more of your own daily life matters.

We can recognize those benefits without telling women to starve themselves, push through pain, or accept blame for having a disease.

Why I am pushing back

When you live with a painful condition, a confident explanation can be powerful.

Finally, someone seems to know what is wrong. Finally, there might be a way forward.

I understand why that gets our attention.

But telling someone their condition will not adequately improve until a particular underlying problem is treated can influence real decisions: where they spend money, which appointments they pursue, and whether they lose confidence in care that may already be helping.

That level of certainty needs support.

Even the 2026 international consensus says researchers are still investigating whether the inflammation seen in lipedema is a cause or a consequence of the condition. That is a substantial unanswered question.

People deserve to hear that uncertainty as clearly as they hear the proposed explanation.

You are allowed to ask for the study

You do not need a medical degree to ask reasonable questions about a medical claim.

Start with these:

• Which study shows that this causes lipedema?
• What actually improved for the people who received the treatment?
• Does that study support the claim you are making?

If the research measured a chemical in a tissue sample, that is what it measured. If it showed symptom improvement, say which symptoms improved and in whom. If reversal has not been demonstrated, make that clear.

We should be able to discuss promising ideas without presenting them as settled answers.

I want mast cells studied. I want nutrition studied. I want every credible possibility investigated carefully enough that we can learn what helps, who it helps, and what the limitations are.

At Core & Curve Lab, that is the standard I want to hold: show the evidence, explain what it means, and be honest about what it cannot tell us yet.

Our pain is real. Our time, money, and hope deserve that level of honesty.

Here is the other thing I want to say plainly. This is exactly why I built Core & Curve Lab. Too many of us are stuck choosing between doctors who have never learned about lipedema and lipedema gurus out to make money off our hope. We deserve better than that false choice. We have to build our own third pathway to truth — one that is grounded in evidence, honest about what is not yet known, and accountable to the women living with this every day.

Built for bodies that don’t have the same capacity every day.

Read the evidence

• Bonetti and colleagues, 2023: tissue histamine findings and the three-person treatment pilot
• Al-Ghadban and colleagues, 2019: immune cells and other findings in lipedema tissue
• American Academy of Allergy, Asthma & Immunology: MCAS evaluation and diagnosis
• Lundanes and colleagues, 2024: randomized trial of diet, pain, and quality of life
• Atan and Bahar-Özdemir, 2021: rehabilitation trial in severe lipedema
• Lipedema World Alliance, 2026: international consensus on definition and management
• Dempsey reel: Instagram, quoted October 29, 2026

This article provides education and commentary on research. Individual diagnosis and treatment require an appropriate clinical assessment.